It takes two peroxisome proliferator-activated receptors (PPAR-β/δ and PPAR-γ) to tango idiopathic pulmonary fibrosis
Respiratory Research · 23.09.2024 · 25 (1)
DOI: 10.1186/s12931-024-02935-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Respiratory Research, online erschienen am 23.09.2024. Verfasst von Eistine Boateng und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Anatomy and Cell Biology, Division of Medical Cell Biology, Justus Liebig University, Aulweg 123, 35392, Giessen, Germany. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, PPAR gamma, PPAR-beta, PPAR delta. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutscher Akademischer Austauschdienst, Leistungsorientierte Mittel der JLU, Justus-Liebig-Universität Gießen.
Abstract (Originalsprache)
Background
Idiopathic pulmonary fibrosis (IPF) is characterized by aberrant lung epithelial phenotypes, fibroblast activation, and increased extracellular matrix deposition. Transforming growth factor-beta (TGF-β)1-induced Smad signaling and downregulation of peroxisomal genes are involved in the pathogenesis and can be inhibited by peroxisome proliferator-activated receptor (PPAR)-α activation. However, the three PPARs, that is PPAR-α, PPAR-β/δ, and PPAR-γ, are known to interact in a complex crosstalk.
Methods
To mimic the pathogenesis of lung fibrosis, primary lung fibroblasts from control and IPF patients with comparable levels of all three PPARs were treated with TGF-β1 for 24 h, followed by the addition of PPAR ligands either alone or in combination for another 24 h. Fibrosis markers (intra- and extracellular collagen levels, expression and activity of matrix metalloproteinases) and peroxisomal biogenesis and metabolism (gene expression of peroxisomal biogenesis and matrix proteins, protein levels of PEX13 and catalase, targeted and untargeted lipidomic profiles) were analyzed after TGF-β1 treatment and the effects of the PPAR ligands were investigated.
Results
TGF-β1 induced the expected phenotype; e.g. it increased the intra- and extracellular collagen levels and decreased peroxisomal biogenesis and metabolism. Agonists of different PPARs reversed TGF-β1-induced fibrosis even when given 24 h after TGF-β1. The effects included the reversals of (1) the increase in collagen production by repressing COL1A2 promoter activity (through PPAR-β/δ activation); (2) the reduced activity of matrix metalloproteinases (through PPAR-β/δ activation); (3) the decrease in peroxisomal biogenesis and lipid metabolism (through PPAR-γ activation); and (4) the decrease in catalase protein levels in control (through PPAR-γ activation) and IPF (through a combined activation of PPAR-β/δ and PPAR-γ) fibroblasts. Further experiments to explore the role of catalase showed that an overexpression of catalase protein reduced collagen production. Additionally, the beneficial effect of PPAR-γ but not of PPAR-β/δ activation on collagen synthesis depended on catalase activity and was thus redox-sensitive.
Conclusion
Our data provide evidence that IPF patients may benefit from a combined activation of PPAR-β/δ and PPAR-γ.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Anatomy and Cell Biology, Division of Medical Cell Biology, Justus Liebig University, Aulweg 123, 35392, Giessen, Germany.
- Department of Medical Education, College of Medicine and Life Sciences, University of Toledo, Toledo, OH, 43614, USA.
- Institute of Inorganic and Analytical Chemistry, Justus Liebig University, 35392, Giessen, Germany.
- Max Planck Institute of Molecular Cell Biology and Genetics, 01307, Dresden, Germany.
- Department of Internal Medicine VIII, Eberhard Karls University, 72076, Tübingen, Germany.
- Department of Internal Medicine II, Member of the German Center for Lung Research (DZL), Universities of Giessen and Marburg Lung Center (UGMLC), Justus Liebig University, 35392, Giessen, Germany.
Förderung
- Deutscher Akademischer Austauschdienst
- Leistungsorientierte Mittel der JLU
- Justus-Liebig-Universität Gießen
Zitieren
APA
Boateng, E., Bonilla-Martinez, R., Ahlemeyer, B., Garikapati, V., Alam, M. R., Trompak, O., Oruqaj, G., El-Merhie, N., Seimetz, M., Ruppert, C., Günther, A., Spengler, B., Karnati, S., & Baumgart-Vogt, E. (2024). It takes two peroxisome proliferator-activated receptors (PPAR-β/δ and PPAR-γ) to tango idiopathic pulmonary fibrosis. Respiratory Research, 25(1). https://doi.org/10.1186/s12931-024-02935-7
Vancouver
Boateng E, Bonilla-Martinez R, Ahlemeyer B, Garikapati V, Alam MR, Trompak O, et al. It takes two peroxisome proliferator-activated receptors (PPAR-β/δ and PPAR-γ) to tango idiopathic pulmonary fibrosis. Respiratory Research. 2024;25(1). doi:10.1186/s12931-024-02935-7
BibTeX
@article{Boateng2024,
author = {Boateng, Eistine and Bonilla-Martinez, Rocio and Ahlemeyer, Barbara and Garikapati, Vannuruswamy and Alam, Mohammad Rashedul and Trompak, Omelyan and Oruqaj, Gani and El-Merhie, Natalia and Seimetz, Michael and Ruppert, Clemens and Günther, Andreas and Spengler, Bernhard and Karnati, Srikanth and Baumgart-Vogt, Eveline},
title = {It takes two peroxisome proliferator-activated receptors (PPAR-β/δ and PPAR-γ) to tango idiopathic pulmonary fibrosis},
journal = {Respiratory Research},
year = {2024},
volume = {25},
number = {1},
doi = {10.1186/s12931-024-02935-7}
}
EUVIMED